US Food and Drug Administration (FDA) commissioner Margaret Hamburg has confirmed that the agency is revoking its approval of the breast cancer indication for Roche's Avastin medication.
US Food and Drug Administration (FDA) commissioner Margaret Hamburg has confirmed that the agency is revoking its approval of the breast cancer indication for Roche’s Avastin medication.
The drug will, however, remain on the market as an approved treatment for particular forms of colon, lung, kidney and brain cancer.
Risks associated with Avastin include high blood pressure, bleeding and haemorrhaging as well as heart attack or failure.
The announcement stems from a decision made in July 2010, in which the FDA Oncologic Drugs Advisory Committee voted 12-1 in favour of removing the drug’s approval.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
Excellence in Action Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.
